Table of Contents
Submission record
Been given: 10 February 2021
Accepted: 23 December 2021
Revealed in print: 25 February 2022
Acknowledgments
Funding: This work was supported by Countrywide Institutes of Health and fitness grant R01 GM081617 (R.Ki.) Israel Science Basis grant 3055/19 inside the Israel Precision Medication Partnership program (R.Ki.), Ernest and Bonnie Beutler Research Application of Excellence in Genomic Drugs (R.Ki.) European Analysis Council FP7 ERC grant 281891 (R.Ki.) Wellcome Trust Sir Henry Wellcome fellowship 204684/Z/16/Z (M.S.) and D. Dan and Betty Kahn Foundation’s reward to the College of Michigan, Weizmann Institute, and Technion–Israel Institute of Engineering Collaboration for Exploration.
Author contributions: M.S., O.S., I.Y., G.K., J.K., G.C., V.S., and R.Ki. made the analyze. R.Ka. and E.H. curated clinical knowledge. M.P., G.R., T.W., O.S., and Y.A. gathered clinical samples. G.R., T.W., G.K., and J.K. handled scientific job administration. M.S., O.S., I.Y., and Y.A. executed total-genome sequencing. M.S. and R.Ki. analyzed the info. M.S., I.Y., O.S., B.F., M.P., G.C., V.S., and R.Ki. interpreted the final results. M.S. and R.Ki. wrote the paper with feedback from all authors.
Competing pursuits: The authors declare that they have no competing interests.